# R&D Impairment

The Price of Ambiguity: Why China’s Cardiovascular Giant Salubris is Crashing

Shenzhen Salubris Pharmaceuticals shares hit consecutive limit-down floors after its flagship heart failure drug failed to show statistically significant results in Phase II trials. The sell-off reflects growing investor impatience with China's biotech sector as companies struggle to transition from generics to true innovation.